Results 61 to 70 of about 4,938,261 (300)

The degree of anisocytosis predicts survival in patients with primary myelofibrosis [PDF]

, 2016
Introduction: Red cell distribution width (RDW) provides a quantitative measure of anisocytosis and it is associated with the presence of subclinical systemic inflammation and a poor outcome in a variety of diseases when elevated.
Hariš, Višnja, Jakšić, Ozren, Kušec, Rajko, Lucijanić, Marko, Mitrović, Zdravko, Pejša, Vlatko, Piršić, Mario, Prka, Željko, Tomasović-Lončarić, Čedna, Vasilj, Tamara, Štoos-Veić, Tajana   +10 more
core   +1 more source

Mutations and prognosis in primary myelofibrosis [PDF]

Leukemia, 2013
Patient outcome in primary myelofibrosis (PMF) is significantly influenced by karyotype. We studied 879 PMF patients to determine the individual and combinatorial prognostic relevance of somatic mutations. Analysis was performed in 483 European patients and the seminal observations were validated in 396 Mayo Clinic patients.
VANNUCCHI, ALESSANDRO MARIA, Lasho TL, GUGLIELMELLI, PAOLA, BIAMONTE, FLAVIA, Pardanani A, Pereira A, Finke C, Score J, Gangat N, MANNARELLI, CARMELA, Ketterling RP, ROTUNNO, GIADA, Knudson RA, Susini MC, Laborde RR, SPOLVERINI, AMBRA, PANCRAZZI, ALESSANDRO, PIERI, LISA, Manfredini R, Tagliafico E, Zini R, Jones A, Zoi K, Reiter A, Duncombe A, Pietra D, Rumi E, Cervantes F, Barosi G, Cazzola M, Cross NC, Tefferi A.   +31 more
openaire   +3 more sources

Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis.

Blood, 2019
Anemia of lower-risk myelodysplastic syndromes (MDSs) and primary myelofibrosis (PMF) generally becomes resistant to available treatments, leading to red blood cell (RBC) transfusions, iron overload, shortened survival, and poor quality of life.
P. Fenaux, J. Kiladjian, U. Platzbecker
semanticscholar   +1 more source

Advances in myelofibrosis: a clinical case approach

Haematologica, 2013
Primary myelofibrosis is a member of the myeloproliferative neoplasms, a diverse group of bone marrow malignancies. Symptoms of myelofibrosis, particularly those associated with splenomegaly (abdominal distention and pain, early satiety, dyspnea, and ...
John O. Mascarenhas, Attilio Orazi, Kapil N. Bhalla, Richard E. Champlin, Claire Harrison, Ronald Hoffman   +5 more
doaj   +1 more source

The diagnosis and management of the haematologic manifestations of lupus [PDF]

, 2016
Haematological manifestations in systemic lupus erythematosus (SLE) are frequently observed. They are diverse and range from mild to severe.
Castro, SG, Isenberg, DA, Velo-García, A   +2 more
core   +1 more source

Mutant calreticulin knockin mice develop thrombocytosis and myelofibrosis without a stem cell self-renewal advantage. [PDF]

, 2018
Somatic mutations in the endoplasmic reticulum chaperone calreticulin (CALR) are detected in approximately 40% of patients with essential thrombocythemia (ET) and primary myelofibrosis (PMF).
Aungier, Juliet, Bennett, Cavan, Dovey, Oliver M, Ghevaert, Cedric, Gonzalez-Arias, Carlos, Green, Anthony R, Grinfeld, Jacob, Hamilton, Tina L, Kent, David G, Klampfl, Thorsten, Li, Juan, Loughran, Stephen, Park, Hyun Jung, Pask, Dean C, Prins, Daniel, Sneade, Rachel, Vassiliou, George S, Williams, Matthew   +17 more
core   +1 more source

Biology and Treatment of Primary Myelofibrosis [PDF]

Hematology, 2007
Abstract Primary myelofibrosis (PMF) is a chronic myeloproliferative disorder associated with an average survival of less than 5 years. Therapy for PMF has used chemotherapeutic agents, immunomodulatory drugs, or biological-response modifiers that have not always been directed at the biological processes that underlie the origins of PMF.
Ronald, Hoffman, Damiano, Rondelli
openaire   +2 more sources

Targeting DESI2 as a Novel Therapeutic Strategy for JAK2‐Mutant Leukemias

Advanced Science, EarlyView.
Mass spectrometry‐based proteomics identify DESI2 as a novel component of the JAK2‐V617F complex, which associates with and stabilizes mutant JAK2 through deSUMOylation and deubiquitination, therefore promoting JAK2 mutant cell growth and MPN disease onset in vivo.
Husheng Mei, Wuqiang Wen, Wenjun Zhang, Shujing Zhang, Ting Sun, Guiming Li, Jing Zhang, Shuang Qi, Jie Zhou, Bing Li, Yunshuo Zhao, Xiaotong Chen, Bowen Li, Yiying Xue, Wang Lu, Yanli Sun, Jingyao Wang, Hengyue Shan, Shengzhe Zhang, Yushan Huang, Yisa Chen, Wenchao Wang, Qingsong Liu, Wenchao Lu, Li Tan, Yi Ding, Jianfei Fu, Jun Long, Lei Zhang, Baobing Zhao, Aibin Liang, Baishan Jiang, Jing Yang   +32 more
wiley   +1 more source

miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells: role of miR-155/JARID2 axis in abnormal megakaryopoiesis [PDF]

, 2014
Primary myelofibrosis (PMF) is a myeloproliferative neoplasm characterized by megakaryocyte (MK) hyperplasia, bone marrow fibrosis, and abnormal stem cell trafficking. PMF may be associated with somatic mutations in JAK2, MPL, or CALR.
Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative, Investigators, Barosi, Giovanni, Bianchi, Elisa, Bisognin, Andrea, Bogani, Costanza, Bortoluzzi, Stefania, Cazzola, Mario, Fanelli, Tiziana, Ferrari, Sergio, Guglielmelli, Paola, Manfredini, Rossella, Mannarelli, Carmela, Norfo, Ruggiero, Pennucci, Valentina, Pietra, Daniela, Prudente, Zelia, Rambaldi, Alessandro, Rontauroli, Sebastiano, Rosti, Vittorio, Ruberti, Samantha, Sacchi, Giorgia, Salati, Simona, Salmoiraghi, Silvia, Tagliafico, Enrico, Vannucchi, Alessandro M, Zini, Roberta   +25 more
core   +1 more source

Population Pharmacokinetics and Exposure–Response Analyses of Momelotinib, Its Active Metabolite (M21), and Total Active Moiety in Myelofibrosis

Clinical Pharmacology &Therapeutics, EarlyView.
Momelotinib, a Janus kinase (JAK) 1/JAK2/activin A receptor type 1 inhibitor, is approved for the treatment of myelofibrosis with anemia. These analyses characterized the population pharmacokinetics of momelotinib and its active metabolite M21 following administration of the commercial tablet formulation in patients with myelofibrosis from phase II/III
Benjamin Rich, Meenakshi Srinivasan, Yu Liu Ho, Sandra A.G. Visser, Geraldine Ferron‐Brady, Georgios Vlasakakis   +5 more
wiley   +1 more source